866-997-4948(US-Canada Toll Free)

Kidney Disease Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 324 Pages


Global Markets Directs, \'Kidney Disease Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Kidney Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Disease. 

Kidney Disease Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Kidney Disease.
  • A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Kidney Disease pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Kidney Disease.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Kidney Disease pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Kidney Disease Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Kidney Disease 12
Kidney Disease Therapeutics under Development by Companies 14
Kidney Disease Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Kidney Disease Therapeutics Products under Development by Companies 28
Kidney Disease Therapeutics Products under Investigation by Universities/Institutes 35
Companies Involved in Kidney Disease Therapeutics Development 37
Bristol-Myers Squibb Company 37
Genzyme Corporation 38
Baxter International Inc. 39
AstraZeneca PLC 40
Eli Lilly and Company 41
Quark Pharmaceuticals, Inc. 42
Cytokine PharmaSciences, Inc. 43
BioLineRx, Ltd. 44
FibroGen, Inc. 45
Novartis AG 46
Astellas Pharma Inc. 47
Eisai Co., Ltd. 48
Kureha Corporation 49
LEO Pharma A/S 50
Zydus Cadila Healthcare Limited 51
Hadasit Medical Research Services & Development Ltd 52
Bayer AG 53
Evotec Aktiengesellschaft 54
Celldex Therapeutics, Inc. 55
Nile Therapeutics, Inc. 56
Osteologix, Inc. 57
Lexicon Pharmaceuticals, Inc. 58
La Jolla Pharmaceutical Company 59
Alexion Pharmaceuticals, Inc. 60
Dynavax Technologies Corporation 61
Theratechnologies Inc. 62
Torrent Pharmaceuticals Limited 63
Ahn-Gook Pharmaceutical Co., Ltd. 64
Proximagen Neuroscience plc. 65
Hansa Medical AB 66
Raptor Pharmaceuticals Corp. 67
Paloma Pharmaceuticals, Inc. 68
Biotecnol SA 69
Am-Pharma B.V. 70
Pharmalink AB 71
Pieris AG 72
Ventria Bioscience 73
AlloCure Inc. 74
Hawthorn Pharmaceuticals, Inc. 75
Promedior, Inc. 76
Catabasis Pharmaceuticals, Inc. 77
TetraLogic Pharmaceuticals 78
Reata Pharmaceuticals, Inc. 79
Indus Biotech Private Limited 80
Angion Biomedica Corp. 81
Thrasos, Inc. 82
Stromedix, Inc. 83
Concert Pharmaceuticals, Inc. 84
CorMedix, Inc. 85
Intercept Pharmaceuticals, Inc. 86
Bolder Biotechnology, Inc. 87
Vitae Pharmaceuticals, Inc. 88
Trius Therapeutics, Inc. 89
Kringle Pharma, Inc. 90
ADIENNE Pharma & Biotech 91
Stelic Institute & Co. 92
Nephrx Corporation 93
Regulus Therapeutics Inc. 94
IGAN Biosciences 95
Ardelyx, Inc. 96
Sorbent Therapeutics, Inc. 97
TheraQuest Biosciences, LLC 98
Vicore Pharma AB 99
Cellmid Ltd 100
InVasc Therapeutics, Inc. 101
Ischemix 102
Kidney Disease Therapeutics Assessment 103
Assessment by Monotherapy Products 103
Assessment by Combination Products 104
Assessment by Route of Administration 105
Assessment by Molecule Type 107
Drug Profiles 110
eribulin mesylate - Drug Profile 110
beraprost sodium - Drug Profile 114
tabalumab - Drug Profile 115
CDX-1189 - Drug Profile 117
CDX-1135 - Drug Profile 118
(AHU-377 + valsartan) - Drug Profile 120
LX-4211 - Drug Profile 122
BMN-185 - Drug Profile 124
FG-3019 - Drug Profile 125
budesonide - Drug Profile 127
TH-0673 - Drug Profile 129
bardoxolone methyl - Drug Profile 130
PRS-080 - Drug Profile 133
Cardiotrophin-1 - Drug Profile 135
eculizumab - Drug Profile 137
Hepatitis B Vaccine - Drug Profile 139
CU-NP - Drug Profile 141
CGEN-856 - Drug Profile 142
AST-120 - Drug Profile 144
LEO-27847 - Drug Profile 146
THR-123 - Drug Profile 147
INDUS-815B - Drug Profile 148
BB-3 - Drug Profile 149
Necrostatin Program - Drug Profile 151
STX-100 - Drug Profile 152
QPI-1002 - Drug Profile 153
siRNA For Chronic Diseases - Drug Profile 155
G Family Inhibitor For CKD - Drug Profile 156
VTP-27999 - Drug Profile 157
CLP-1004 - Drug Profile 158
Recombinant Human Hepatocyte Growth Factor - Drug Profile 159
tedizolid phosphate - Drug Profile 161
GCS-100 - Drug Profile 163
P-529 - Drug Profile 165
INT-767 - Drug Profile 168
atrasentan hydrochloride - Drug Profile 169
AP-214 - Drug Profile 170
Neo-Kidney Augment - Drug Profile 172
Neo-Kidney Augment - Drug Profile 173
MTP-131 - Drug Profile 174
deferiprone - Drug Profile 176
deferiprone - Drug Profile 178
NX-001 - Drug Profile 180
Recombinant Human Alkaline Phosphatase - Drug Profile 181
Haw Nuv-15 - Drug Profile 183
Haw Nuv-16 - Drug Profile 184
BBT-045 - Drug Profile 185
(losartan potassium + alpha lipoic acid) - Drug Profile 186
bemiparin - Drug Profile 187
MIF Inhibitors - Drug Profile 189
ABT-614 - Drug Profile 190
LY-2623091 - Drug Profile 191
Prod-1 - Drug Profile 192
AM-095 - Drug Profile 193
PEG-EPO - Drug Profile 194
mepivacaine hydrochloride - Drug Profile 195
HYPER-IL-6 - Drug Profile 197
ZS-9 - Drug Profile 198
PanCyte - Drug Profile 199
CTP-499 - Drug Profile 200
BCT-197 - Drug Profile 202
PRM-151 Subcutaneous - Drug Profile 203
AZD-1722 - Drug Profile 204
BHQ-880 - Drug Profile 206
Anti microRNA-21 - Drug Profile 208
TRC-160334 - Drug Profile 209
BBT-021 - Drug Profile 211
BAX-69 - Drug Profile 212
Compound-21 - Drug Profile 214
THR-184 - Drug Profile 216
AC-607 - Drug Profile 217
BR-5489 - Drug Profile 219
ANG-3070 - Drug Profile 221
ANG-4011 - Drug Profile 222
F-351 - Drug Profile 223
LJPC-101 - Drug Profile 225
RDX-002 - Drug Profile 226
CMX-272XX - Drug Profile 227
RDX-5791 + Enalaprilat - Drug Profile 228
AGNPN-803 - Drug Profile 229
Anti-MIF Receptor Technology Platform - Drug Profile 230
MultiGeneGraft - Drug Profile 231
ANG-3298 - Drug Profile 232
EndoS - Drug Profile 233
Drug For Chronic Kidney Disease - Drug Profile 234
CCR2 Antagonist - Drug Profile 235
3-Acetyl-5-Methyltetronic Acid - Drug Profile 236
CXA-10 - Drug Profile 237
cysteamine - Drug Profile 238
optibumin Biosimilar - Drug Profile 239
TRPM7 Inhibitor Program - Drug Profile 240
CAT-4001 - Drug Profile 241
Galectin-3 Inhibitors - Drug Profile 242
RDX-013 - Drug Profile 243
AVX-003 - Drug Profile 244
1D-11 - Drug Profile 245
Drug For Kidney Diseases - Drug Profile 246
N-001 - Drug Profile 247
NYK-0041 - Drug Profile 248
adrecizumab - Drug Profile 249
IkT-001 Pro - Drug Profile 250
CT-140 - Drug Profile 251
Anti-Midkine Antibody - Drug Profile 252
Chronic Kidney Disease Program - Drug Profile 253
Kidney Disease Therapeutics Drug Profile Updates 254
Kidney Disease Therapeutics Discontinued Products 303
Kidney Disease Therapeutics - Dormant Products 304
Kidney Disease Product Development Milestones 309
Featured News & Press Releases 309

Appendix 316
Methodology 316
Coverage 316
Secondary Research 316
Primary Research 316
Expert Panel Validation 316
Contact Us 317
Disclaimer 317

List of Table


Number of Products Under Development for Kidney Disease, H1 2013 19
Products under Development for Kidney Disease Comparative Analysis, H1 2013 20
Number of Products under Development by Companies, H1 2013 22
Number of Products under Development by Companies, H1 2013 (Contd..1) 23
Number of Products under Development by Companies, H1 2013 (Contd..2) 24
Number of Products under Development by Companies, H1 2013 (Contd..3) 25
Number of Products under Development by Companies, H1 2013 (Contd..4) 26
Number of Products under Development by Companies, H1 2013 (Contd..5) 27
Number of Products under Investigation by Universities/Institutes, H1 2013 29
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 30
Comparative Analysis by Late Stage Development, H1 2013 31
Comparative Analysis by Mid Clinical Stage Development, H1 2013 32
Comparative Analysis by Early Clinical Stage Development, H1 2013 33
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 34
Products under Development by Companies, H1 2013 35
Products under Development by Companies, H1 2013 (Contd..1) 36
Products under Development by Companies, H1 2013 (Contd..2) 37
Products under Development by Companies, H1 2013 (Contd..3) 38
Products under Development by Companies, H1 2013 (Contd..4) 39
Products under Development by Companies, H1 2013 (Contd..5) 40
Products under Development by Companies, H1 2013 (Contd..6) 41
Products under Investigation by Universities/Institutes, H1 2013 42
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 43
Bristol-Myers Squibb Company, H1 2013 44
Genzyme Corporation, H1 2013 45
Baxter International Inc., H1 2013 46
AstraZeneca PLC, H1 2013 47
Eli Lilly and Company, H1 2013 48
Quark Pharmaceuticals, Inc., H1 2013 49
Cytokine PharmaSciences, Inc., H1 2013 50
BioLineRx, Ltd., H1 2013 51
FibroGen, Inc., H1 2013 52
Novartis AG, H1 2013 53
Astellas Pharma Inc., H1 2013 54
Eisai Co., Ltd., H1 2013 55
Kureha Corporation, H1 2013 56
LEO Pharma A/S, H1 2013 57
Zydus Cadila Healthcare Limited, H1 2013 58
Hadasit Medical Research Services & Development Ltd, H1 2013 59
Bayer AG, H1 2013 60
Evotec Aktiengesellschaft, H1 2013 61
Celldex Therapeutics, Inc., H1 2013 62
Nile Therapeutics, Inc., H1 2013 63
Osteologix, Inc., H1 2013 64
Lexicon Pharmaceuticals, Inc., H1 2013 65
La Jolla Pharmaceutical Company, H1 2013 66
Alexion Pharmaceuticals, Inc., H1 2013 67
Dynavax Technologies Corporation, H1 2013 68
Theratechnologies Inc., H1 2013 69
Torrent Pharmaceuticals Limited, H1 2013 70
Ahn-Gook Pharmaceutical Co., Ltd., H1 2013 71
Proximagen Neuroscience plc., H1 2013 72
Hansa Medical AB, H1 2013 73
Raptor Pharmaceuticals Corp., H1 2013 74
Paloma Pharmaceuticals, Inc., H1 2013 75
Biotecnol SA, H1 2013 76
Am-Pharma B.V., H1 2013 77
Pharmalink AB, H1 2013 78
Pieris AG, H1 2013 79
Ventria Bioscience, H1 2013 80
AlloCure Inc., H1 2013 81
Hawthorn Pharmaceuticals, Inc., H1 2013 82
Promedior, Inc., H1 2013 83
Catabasis Pharmaceuticals, Inc., H1 2013 84
TetraLogic Pharmaceuticals, H1 2013 85
Reata Pharmaceuticals, Inc., H1 2013 86
Indus Biotech Private Limited, H1 2013 87
Angion Biomedica Corp., H1 2013 88
Thrasos, Inc., H1 2013 89
Stromedix, Inc., H1 2013 90
Concert Pharmaceuticals, Inc., H1 2013 91
CorMedix, Inc., H1 2013 92
Intercept Pharmaceuticals, Inc., H1 2013 93
Bolder Biotechnology, Inc., H1 2013 94
Vitae Pharmaceuticals, Inc., H1 2013 95
Trius Therapeutics, Inc., H1 2013 96
Kringle Pharma, Inc., H1 2013 97
ADIENNE Pharma & Biotech, H1 2013 98
Stelic Institute & Co., H1 2013 99
Nephrx Corporation, H1 2013 100
Regulus Therapeutics Inc., H1 2013 101
IGAN Biosciences, H1 2013 102
Ardelyx, Inc., H1 2013 103
Sorbent Therapeutics, Inc., H1 2013 104
TheraQuest Biosciences, LLC, H1 2013 105
Vicore Pharma AB, H1 2013 106
Cellmid Ltd, H1 2013 107
InVasc Therapeutics, Inc., H1 2013 108
Ischemix, H1 2013 109
Assessment by Monotherapy Products, H1 2013 110
Assessment by Combination Products, H1 2013 111
Assessment by Stage and Route of Administration, H1 2013 113
Assessment by Stage and Molecule Type, H1 2013 116
Kidney Disease Therapeutics Drug Profile Updates 260
Kidney Disease Therapeutics Discontinued Products 309
Kidney Disease Therapeutics Dormant Products 310
Kidney Disease Therapeutics Dormant Products (Contd..1) 311
Kidney Disease Therapeutics Dormant Products (Contd..2) 312
Kidney Disease Therapeutics Dormant Products (Contd..3) 313
Kidney Disease Therapeutics Dormant Products (Contd..4) 314

List of Chart


Number of Products under Development for Kidney Disease, H1 2013 19
Products under Development for Kidney Disease Comparative Analysis, H1 2013 20
Products under Development by Companies, H1 2013 21
Products under Investigation by Universities/Institutes, H1 2013 28
Late Stage Products, H1 2013 31
Mid Clinical Stage Products, H1 2013 32
Early Clinical Stage Products, H1 2013 33
Discovery and Pre-Clinical Stage Products, H1 2013 34
Assessment by Monotherapy Products, H1 2013 110
Assessment by Combination Products, H1 2013 111
Assessment by Route of Administration, H1 2013 112
Assessment by Stage and Route of Administration, H1 2013 113
Assessment by Molecule Type, H1 2013 114
Assessment by Stage and Molecule Type, H1 2013 115

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *